Found 30 clinical trials
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
- 167 views
- 08 Nov, 2020
- 1 location
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
- 2367 views
- 23 Nov, 2020
- 18 locations
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
- 290 views
- 08 Nov, 2020
- 1 location
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis
patients treated with a combination of MTX and biologic as second-line therapy. Less than 10% of patients treated with a combination of MTX and another targeted DMARD, such as baricitinib, as
- 0 views
- 21 Jul, 2021
- 20 locations
Study to Demonstrate the Efficacy Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- 84 views
- 16 May, 2021
- 89 locations
Study to Demonstrate the Efficacy Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
Week 16 despite current or previous NSAID, DMARD and/or anti Tumor Necrosis Factor (TNF) therapy. In addition, to further support efficacy and safety of an i.v. regimen, data will be collected for up
- 59 views
- 27 Aug, 2021
- 110 locations
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
This study [contRAst 2 (201791: NCT03970837)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to csDMARD(s) or …
- 340 views
- 14 May, 2021
- 224 locations
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment
A potential application of therapeutic drug monitoring is to predict efficacy after switch to another biological in the case of inefficacy of the previous TNF-inhibitor (TNFi) in rheumatoid arthritis (RA) patients. It has been shown that when antidrug antibodies against adalimumab are detected (resulting in lower drug serum concentrations) in …
- 3 views
- 22 Jun, 2021
- 2 locations
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm …
- 2 views
- 05 May, 2021
- 1 location
Methotrexate and Metformin in Rheumatoid Arthritis Patients
Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and anti-inflammatory properties make it a good candidate for …
- 0 views
- 27 Jan, 2021
- 11 locations